"solitary lesion > 2 cm or early multifocal disease characterised by up to 3 lesions measuring less than 3 cm"
"PS > 2"
"Child-Pugh score"
"Child-Pugh A"
"If not a candidate for resection or transplant: ablation (RFA/MWA), TARE, or EBRT are now all considered valid alternatives, with the choice tailored to patient and tumour characteristics 3"
"If not a candidate for resection or transplant: ablation (RFA/MWA), TARE, or EBRT are now all considered valid alternatives, with the choice tailored to patient and tumour characteristics 3"
"If not a candidate for resection or transplant: ablation (RFA/MWA), TARE, or EBRT are now all considered valid alternatives, with the choice tailored to patient and tumour characteristics 3"
"Note: TARE and EBRT have been formally included in 2025 review as ablative options for BCLC-0, supported by new evidence 3"
"Note: TARE and EBRT have been formally included in 2025 review as ablative options for BCLC-0, supported by new evidence 3"
"If not eligible for above: TARE and EBRT may be considered in selected cases, but evidence is less robust than for ablation"
"If not eligible for above: TARE and EBRT may be considered in selected cases, but evidence is less robust than for ablation"
"TARE and EBRT may be considered for patients not candidates for TACE, but not as first-line options"
"TARE and EBRT may be considered for patients not candidates for TACE, but not as first-line options"
"second-line: regorafenib (if sorafenib-tolerant), cabozantinib, ramucirumab (AFP >400 ng/mL)"
"TARE/EBRT may be considered if systemic therapy is contraindicated or not feasible, especially in macrovascular invasion, but evidence is limited 3"
"TARE/EBRT may be considered if systemic therapy is contraindicated or not feasible, especially in macrovascular invasion, but evidence is limited 3"
"If decompensation is potentially reversible (e.g., after abstinence or viral eradication), patients may re-enter treatment pathways"
"single HCC: resection (minimally invasive preferred) if no CSPH; otherwise, transplant or ablation"
"multifocal (≤3 nodules, each ≤3 cm): transplant is preferred; ablation if transplant not feasible 3"
"single HCC: resection (minimally invasive preferred) if no CSPH; otherwise, transplant or ablation"